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The interaction between the fragile X mental retardation protein (FMRP) and BC1 RNA has been the subject of controversy.
We probed the parameters of RNA binding to FMRP in several ways. Nondenaturing agarose gel analysis showed that BC1 RNA
transcripts produced by in vitro transcription contain a population of conformers, which can be modulated by preannealing.
Accordingly, FMRP differentially binds to the annealed and unannealed conformer populations. Using partial RNase digestion,
we demonstrate that annealed BC1 RNA contains a unique conformer that FMRP likely binds. We further demonstrate that
this interaction is 100-fold weaker than that the binding of eEF-1A mRNA and FMRP, and that preannealing is not a general
requirement for FMRP’s interaction with RNA. In addition, binding does not require the N-terminal 204 amino acids of FMRP,
methylated arginine residues and can be recapitulated by both fragile X paralogs. Altogether, our data continue to support a model
in which BC1 RNA functions independently of FMRP.
1. Introduction
Fragile X syndrome is the most common inherited cause
of mental impairment accounting for ca. 40% of X-linked
mental retardation cases. It is also the most common known
cause of autism (reviewed in [1–6]). Other characteristics of
the fragile X syndrome include hyperactivity [7], increased
susceptibility to seizures [8], increased testicular volume
[9], macrocephaly, and large ears [10]. In addition, it has
been found that carriers of the fragile X premutation,
once thought to be free of the effects of the disease, also
suffer from subtle behavioral and physical abnormalities
[11–14]. This wide and varied constellation of phenotypic
features results from the loss of function of a single
gene, FMR1 (summarized in: http://www.ncbi.nlm.nih.gov/
bookshelf/br.fcgi?book=gene&part-fragilex).
The FMR1 gene encodes the RNA-binding protein FMRP
[15], a negative [16–18] and positive [19, 20] translational
regulator, and it has been of considerable interest to delineate
the cellular RNAs that bind to FMRP [21–25] and the
mechanism(s) by which FMRP binds and controls these
mRNAs [26–35].
In 2003, Zalfa et al. described a bridging mechanism
in which the fragile X mental retardation protein (FMRP)
via interaction with the 5′ end of the small noncoding
RNA, BC1, and bound and repressed FMRP target mRNAs
[36]. This model has been subject to great deal of scrutiny
owing to findings that appear to be out of step with other
studies. These include differences in the prime localization
of FMRP with small repressed mRNPs rather than brain
polyribosomes [18, 37–39], differences in the interpretation
of the interaction of FMRP with BC1 RNA as specific and
significant [40] rather than nonspecific and insignificant [30,
41, 42] and detailed mechanistic differences in the nature of
BC1 RNA-mediated localization and translational repression
[41, 43–45]. In response to some of these criticisms, Zalfa
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and Bagni reposited that their model, rather than being a
general model of FMRP-mRNA interactions, was only one of
several possible models [46].
More recent investigations of some of the concomitants
of the Zalfa model [47] found that the interaction of recom-
binant FMRP with BC1 RNA was weak compared to that
of a G-quartet-containing RNA. Furthermore, its strength
varied significantly depending upon the buffer conditions
used. The data suggested that FMRP may interact with a
particular conformer of BC1 RNA. Here, we elaborate the
conditions and requirements for a weak FMRP BC1 RNA in
vitro interaction.
2. Materials and Methods
2.1. Buffers. Z-buffer is 10 mM Tris-HCl pH 7.5,
2 mM MgCl2, 400 mM NaCl and 0.2% SDS [36]. The
RNA-binding buffer that was used for affinity capture is
50 mM Tris-HCl, pH 7.4, 2 mM MgCl2, and 150 mM KCl,
1 mM EDTA, and 1 mM DTT [26]. Structure buffer is
10 mM Tris-HCl pH 7, 100 mM KCl, and 10 mM MgCl2.
2.2. Preparation of BC1 RNA Transcripts. Dra I linearized
pBCX607 containing the entire BC1 sequence [48], AvaII
linearized pBCX607 containing the first 65 b of BC1, Sac I
linearized pMK-1 containing the last 60 b of BC1 RNA, a
PCR fragment encoding a T7 RNA polymerase promoter
and the first 75 b of BC1 RNA, Hind III linearized pTAR
encoding an 85 b transcript that folds into a 57 b TAR
element and a 28 b leader sequence and linearized pTri-XEF1
encoding eEF-1A mRNA (Ambion) were used to produce
biotinylated RNAs via in vitro transcription (Ambion).
Plasmids pBCX607 and pMK-1 were provided by Dr. Henri
Tiedge (SUNY Brooklyn). Alcohol-precipitated RNAs were
dissolved in 50 μL DEPC-treated H2O and quantified spec-
trophotometrically. RNA integrity was examined by agarose
gel electrophoresis. For examining the effect of annealing on
RNA-protein interactions, individual RNAs were heated in
1x transcription buffer (Ambion) at 65◦C for 10 min and
then allowed to cool slowly to room temperature for one
hour prior to their use. Note. We obtained identical results
using Z-buffer in the annealing reaction (not shown).
2.3. RNA-Binding Assays. 35S-FMRP, 35S-FMRP280, 35S-
FMRP204, 35S-FXR1P, 35S-FXR2P, 35S-eIF4A, and 35S-
luciferase and were produced from plasmids pET21A-FMRP,
pND-L-mHisFMRP, pET9-FMRP280, pET9-FMRP204, pHA-
FXR1P, and pET21b-FXR2P in an RRL-coupled transcrip-
tion-translation system (Promega). Plasmid pHA-FXR1P
was provided by Dr. Gideon Dreyfuss (University of Penn-
sylvania); plasmids pET9-FMRP280 and pET9-FMRP204 were
provided by Dr. Darryl Spinner (IBR), plasmid pET21b-
FXR2P was a gift from Dr. Jennifer Darnell (Rockefeller
University) and plasmid pET-His6-eIF4A was a gift from
Dr. Henri Tiedge (SUNY Brooklyn). Briefly, 35S-labeled-
proteins were produced by combining twenty five microliters
of TNT rabbit reticulocyte lysate (RRL) with 2 μL of TNT
T7 RNA polymerase, 1 μL of 1 mM amino acid mix minus-
methionine, 35 μCi of 35S-methionine, 1 μL of RNasin and
1 μg of plasmid DNA in a total volume of 50 μL. One
microliter of a 50X Complete protease inhibitor cocktail
was added to prevent proteolysis. Samples were incubated at
30◦C for 90 min and then assayed for protein production by
autoradiography.
Affinity capture assays were performed as described pre-
viously [17]; the bound and unbound products were resolved
by SDS-PAGE and subject to autoradiography.
Autoradiograms were quantified using UN-SCAN-IT Gel
6.1 (Silk Scientific, Inc.). The percent binding was calculated
as
%Binding = 100× Intensitybound[
Intensitybound + Intensityunbound
] . (1)
The percent binding of the “no RNA” control in each exper-
imental set was subtracted from that of the samples; the
difference, representing authentic binding, was plotted.
2.4. RNA Structure Studies. Annealed and unannealed BC1
RNA, BC1 fragment RNAs and control RNAs (1-2 μg),
were treated at room temperature for 15 min with various
amounts of ribonuclease V1 (cobra venom) or ribonuclease
A in structure buffer as indicated. Reaction products were
resolved on 1-2% TAE agarose gels containing 0.1 μg/mL
ethidium bromide along with appropriate size markers. Gels
were imaged using a Scion CFW-1308 M mega pixel camera
and captured in inverted mode using FOTO/Analyst PC
Image software version 9.04 (FOTODYNE). The resulting
image files were digitized and analyzed using UN-SCAN-IT
Gel 6.1.
2.5. RNA Secondary Structure Modeling. RNA lowest energy
secondary structures were determined using the Zuker
algorithm, M-fold (http://mfold.rna.albany.edu).
3. Results and Discussion
3.1. Affinity Capture of FMRP with Biotinylated RNA. Several
methods have been used to assess the direct physical
interaction of FMRP with RNA in vitro. These include pull-
down assays with homoribopolymers [15, 21, 49, 50], affinity
capture using biotinylated RNA [21, 41, 51–53], affinity
capture using immobilized protein [16], UV crosslinking
[21, 49], filter-binding assays [22, 30, 41], electrophoretic
mobility shift assays (EMSA) [26, 36, 40, 42, 47, 54], and
agarose electrophoretic mobility shift assays (AGESA) [17,
41]. Each of these methods has its unique experimental
advantages [55]. Acknowledging that binding between a
nucleic acid and RNA-binding protein (RBP) can be affected
by differences in posttranslational modification [56] and/or
differences between different protein variants [57, 58] our
working hypothesis is that given a particular RBP, a particular
RNA and a defined buffer each of these methods should
converge to produce a common answer. While extensively
studied, FMRP’s interactions with RNA have not always been
examined with this hypothesis in mind Table 1, and it has
been suggested that differences in experimental conditions
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Table 1: Binding conditions used to measure the interaction between FMRP and RNA.
Publication Assay Conditions
Ashley et al. (1993) [51] Pull-down
16 mM HEPES-KOH pH 7.9, 120 mM KCI, 0.04% Nonidet P-40, 1 mg/mL BSA,
0.16 mM dithioerythritol, 0.4 mM phenylmethylsulfonyl fluoride
Brown et al. (1998) [49] Pull-down
10 mM Tris-HCl pH 7.5, 2.5 mM MgCl2, 100 mM NaCl, 2.5% Trition X100,
1 mg/mL heparin
Price et al. (1996) [52] Pull-down
20 mM Hepes, pH 7.9, 2 mM MgCl2, 10 mM ZnCl2, 70 mM NH4Cl, 0.02% Nonidet
P-40, 5 mg/mL yeast tRNA
Sung et al. (2000) [21]
Pull-down
Filter-Binding
20 mM Hepes, pH 7.9, 2 mM MgCl2, 10 mM ZnCl2, 70 mM NH4Cl, 0.02% Nonidet
P-40, 5 mg/mL yeast tRNA
Denman and Sung (2002)
[57]
Pull-down
20 mM Hepes, pH 7.9, 2 mM MgCl2, 10 mM ZnCl2, 70 mM NH4Cl, 0.02% Nonidet
P-40, 5 mg/mL yeast tRNA
Schaeffer et al. (2001) [26] EMSA
50 mM Tris-HCl pH 7.4, 1 mM MgCl2, 1 mM EDTA, 150 mM KCl, 1 mM DTT,
0.25 mg/mL of E.coli tRNA, 0.01% BSA, 8 U of RNasin
Sung et al. (2003) [17]
Pull-down
EMSA
50 mM Tris-HCl, pH 7.0, 2 mM MgCl2, 150 mM NaCl, 1 mM DTT, 0.25 mg/mL
E.coli tRNA, 0.25 mg/mL BSA
Bechara et al. (2006) [61] EMSA
50 mM Tris-HCl pH 7.4, 1 mM MgCl2, 1 mM EDTA, 150 mM KCl, 1 mM DTT,
0.25 mg/mL of E.coli tRNA, 0.01% BSA, 8 U of RNasin
Didiot et al. (2008) [54] EMSA
50 mM Tris-HCl pH 7.4, 1 mM MgCl2, 1 mM EDTA, 150 mM KCl, 1 mM DTT,
0.25 mg/mL of E. coli tRNA, 0.01% BSA, 8 U of RNasin
Zalfa et al. (2003) [36] EMSA
10 mM HEPES pH 7.9, 3 mM MgCl2, 10 mM DTT, 100 mM KCl, 750 mM NaCl, 5%
glycerol, 7 mM β-Mercaptoethanol, 1 mg/mL Albumin, 1.3 mg/mL Heparin
Zalfa et al. (2005) [40] EMSA
20 mM HEPES-KOH, pH 7.6, 5 mM MgCl2, 300 mM KCl, 2 mM DTT, 5% glycerol,
and 500 ng of total yeast tRNA or 20 μg of heparin.
Darnell et al. (2001) [22] Filter-Binding 10 mM Tris-OAc pH 7.7, 200 mM KOAc, 5 mM MgOAc2
Darnell et al. (2005) [30] Filter-Binding
50 mM Tris-OAc at pH 7.7, 50 mM KOAc, 10 mM DTT, 5 mM Mg(OAc)2, 30 μg/mL
tRNA
Gabus et al. (2004) [42] EMSA 20 mM Tris-HCl pH 7.5, 30 mM NaCl, 0.2 mM MgCl2, 5 mM DTT, 10 μM ZnCl2
Laggerbauer et al. (2001)
[16]
Pull-down PBS, 0.02% IGEPAL, 1% BSA
Siomi et al. (1993) [15] Pulldown 10 mM Tris-HCl pH 7.4, 2.5 mM MgCl2, 0.5% Triton X-100, 100–1000 mM NaCl
Stetler et al. (2005) [56] Pulldown




EMSA 50 mM Tris-HCl pH 7.5, 150 mM NaCl and protease inhibitors
Fahling et al. (2009) [20] EMSA
10 mM Hepes pH 7.2, 3 mM MgCl2, 5% glycerol, 1 mM DTT, 150 mM KCl, 2 U/μL
RNaseOUT, 0.5 μg/μL rabbit rRNA
Zou et al. (2008) [63] AGESA 20 mM Tris-HCl pH 7.2, 150 mM NaCl
Iacoangeli et al. (2008) [47] EMSA
50 mM Tris-HCl pH 7.6, 150 mM KCl, 1 mM MgCl2, 1 mM EDTA, 1 mM DTT,
0.2 U/μL
RNase inhibitor, 100 ng/μL total yeast tRNA, and 100 ng/μL BSA
Sets of binding conditions are grouped by the different laboratories that used them. Each set of conditions is differentiated from the next by a dotted line. In
some instances the same group used multiple sets of binding conditions in multiple publications.
and protein preparations form the basis for the divergent
results obtained for the FMRP BC1 RNA interaction [59, 60].
We chose to examine heretofore unstudied aspects of
FMRP’s interaction with BC1 RNA-using affinity capture,
one of the older techniques used in FMRP RNA binding
studies. We next sought a basic buffer to use. In several
previous publications, we have used a buffer described by
Schaeffer et al. [26], which used physiological saline [17, 41,
47], Table 1. However, this buffer contains tRNA to reduce
nonspecific binding, and as two publications demonstrate
that FMRP can interact with tRNA [42, 47], we first
determined whether specific binding between FMRP and
RNA could be observed without the addition of tRNA.
As shown in Figure 1 (upper panel), in the presence of
physiological salt and in the absence of RNA, 35S-FMRP
produced by in vitro translation in rabbit reticulocyte lysate
(RRL) nonspecifically bound to the avidin affinity column;
however, addition of increasing amounts of NaCl decreased
this nonspecific interaction so that at 125 mM NaCl the
amount of bound FMRP was between 5%–10% of the total.
As expected, tRNA also blocked the association of full-length
FMRP to the avidin column, Figure 1 (lower panel). Thus,
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Figure 1: NaCl blocks nonspecific binding of FMRP with avidin. (a) 35S-FMRP was bound to SoftLink resin in 1x Schaeffer binding buffer
supplemented with 0 mM, 125 mM, 250 mM and 375 mM NaCl, lanes 2–5, respectively. Bound 35S-FMRP was recovered, resolved by SDS-
PAGE and subject to autoradiography. Lane 1 shows the amount of 35S-FMRP input into the assay. (b) 35S-FMRP was bound to SoftLink
resin in 1x Schaeffer binding buffer supplemented with 0.05 mg/mL, 0.1 mg/mL, 0.15 mg/mL, and 0.25 mg/mL tRNA, lanes 2–5, respectively.
Bound 35S-FMRP was recovered, resolved by SDS-PAGE and subject to autoradiography. Lane 1 shows the amount of 35S-FMRP input into
the assay. The asterisk marks a 35S-truncation product produced by transcription/translation.
Schaeffer buffer supplemented with 125 mM NaCl blocks the
non-specific interaction of FMRP with the affinity matrix as
effectively as Schaeffer buffer supplemented with tRNA.
3.2. Prior Annealing of BC1 RNA Enhances Its Interaction
with FMRP. Having established this basic set of conditions,
we applied them to study the FMRP BC1 RNA interaction.
The weak binding between FMRP and BC1 RNA that occurs
in protein excess [36] suggested that the protein might
be surveying the population of BC1 RNA conformers and
interacting with a particular one. As BC1 RNA is known
to form higher order structure [45], we performed a simple
experiment to perturb the conformer population that would
test this hypothesis. BC1 RNA was transcribed in vitro and
purified by salt and alcohol precipitation; then, it was either
heated briefly or left untreated. Each RNA (annealed and
unannealed, resp.) was then was titrated with a constant
amount of 35S-FMRP, and the binding was assessed by
affinity capture. Under the conditions used, unannealed
BC1 RNA bound extremely weakly at all concentrations
examined, in concert with previous obtained results [41, 64].
On the other hand, annealed BC1 RNA exhibited stronger
binding to FMRP over the range of concentrations examined,
Figures 2(a) and 2(b).
To index the above results to a known standard, the inter-
action between eEF-1A mRNA and FMRP was also measured
in parallel. Previous work had shown that this RNA binds
strongly to FMRP, without prior annealing [17, 41]. As
expected, the FMRP eEF-1A mRNA interaction was much
stronger than the FMRP BC1 RNA interaction, Figure 2(c).
In fact, with the same amount of 35S-FMRP, unannealed
eEF-1A mRNA evinced saturable binding at 90 nM RNA,
while it took 100-fold more annealed BC1 RNA to achieve
comparable binding; see Figure 2(d).
To determine whether annealing affected the interaction
of FMRP with eEF-1A mRNA, binding to annealed and
unannealed forms of the message was assessed using a
subsaturating concentration of eEF-1A RNA. As shown in
Figure 2(e), binding of eEF-1A mRNA to 35S-FMRP was not
markedly affected by annealing.
3.3. Annealing Alters the Structure of BC1 RNA. The above
data implied that the conformer populations of annealed
and unannealed BC1 RNA differ. To determine whether this
was so, the annealed and unannealed BC1 RNAs used in
Figure 2 were treated with RNases whose cleavage depends
on known RNA structural features and the products were
resolved on nondenaturing agarose gels. In the absence of
treatment, both RNAs displayed a major band as well as a less
prominent, slower migrating band, Figure 3(b). These data
indicate that annealed BC1 RNA and unannealed BC1 RNA
contained multiple conformers. Interestingly, in the presence
of RNase A, which preferentially cleaves at single-stranded
C and U residues, both annealed and unannealed BC1 RNA
behaved nearly identically and were completely degraded by
all but the lowest amount of the enzyme. However, when the
RNAs were treated with a range of concentrations of RNase
V1 (0.01–1 units), which cleaves base-paired nucleotides,
the unannealed form was refractory to cleavage, while the
annealed form was sensitive toward cleavage at the highest
amount, Figure 3(c) (upper panel). Increasing the amount of
RNase V1 recapitulated the sensitivity of annealed BC1 RNA,
Figure 3(c) (lower panel); however, it also demonstrated that
a fraction of unannealed BC1 RNA also contained RNase
V1-sensitive stable duplex RNA. To determine whether the
unique BC1 RNA conformer(s) produced by annealing could
be stabilized by Mg+2 the annealing reaction was also carried
out in the presence of 2 mM MgCl2. The results indicated
that the magnesium did not alter the distribution of BC1
Journal of Nucleic Acids 5
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Figure 2: FMRP interacts weakly with annealed BC1 RNA. Equal amounts of 35S-FMRP was titrated with various amounts of (a) unannealed
biotinylated-BC1 RNA, (b) annealed biotinylated-BC1 RNA, and (c) unannealed biotinylated-eEF-1A RNA, as indicated. Bound (B) and
unbound (U) 35S-FMRP was recovered, resolved by SDS-PAGE and subject to autoradiography. Nonspecific binding to the SoftLink avidin
resin is shown in the -RNA lanes. (d) Graphical analysis of the above data for 4 reactions per concentration. (e) Binding of annealed or
unannealed eEF1A RNA (60 nM) to 35S-FMRP. The percent binding corrected for background of 4 reactions per RNA type is plotted (P = .45
by ANOVA).
RNA conformer(s) or affect their resistance to RNase V1 (not
shown).
These data unequivocally demonstrate that the con-
former populations of annealed and unannealed BC1 RNA
differ, and this difference is due to an increase in the amount
of stable RNA duplexes in the annealed RNA. Moreover, the
data support the hypothesis that the binding between FMRP
and annealed BC1 RNA results from a unique conformer
that is absent from the unannealed BC1 RNA conformer
population.
3.4. Functional Dissection of the FMRP BC1 RNA Interaction.
BC1 RNA contains several distinct higher order structural
elements. Its 5′ end contains two cis-acting spatial targeting
elements, DTE1 and DTE2 [45]. The former is required
for somatic export of BC1 RNA into dendrites, while the
latter specifies long-range distal delivery and is mediated
by a prominent GA-type kink turn (KT) motif in the
apical region of the 5′ BC1 domain [45]. The 3′ 60
bases of BC1 RNA contains an abbreviated A-rich region
and a 3′-terminal stem-loop structure [65] that has been
shown to bind synergistically to the eucaryotic initiation
factor 4A (eIF4A) and the polyadenylation binding protein
(PABP) [41]. To further probe this interaction, BC1 RNA
was functionally dissected, and these two elements were
examined individually. As shown in Figure 4(a), RNase VI
treatment of the 5′ 75 bases of BC1 RNA recapitulated the
results of full-length BC1 RNA indicating that it forms a
stable secondary structure in the absence of the 3′ end.
This agrees with modeling studies using the Zuker M-fold
6 Journal of Nucleic Acids
Annealed Unannealed
Annealed Unannealed
0 0.1 0.01 0 0.111 0.01
M
(ng)
0 0.1 0.01 0.001 0 0.1 0.01 0.001 Units (µL)

































































Figure 3: Annealed BC1 RNA and unannealed BC1 RNA differ structurally. (a) Secondary structure model of BC1 RNA from M-fold. Black
arrows indicate potential RNase VI cleavage sites (both sides of the stem); gray arrows mark potential RNase A cleavage sites. (b) Serial
treatment of annealed and unannealed full-length BC1 RNA with RNase A starting at 1 ng as indicated. (c) Ten-fold serial treatment of
annealed and unannealed full-length BC1 RNA with RNase VI starting with 0.1 units/μL (upper panel), or 0.5 units/μL (lower panel) as
indicated. RNA was visualized by ethidium bromide staining. Arrows mark the major conformers that can be resolved in this system. Lane
M shows 100 bp molecular weight markers.
algorithm, which show that the first 75 bases of BC1 RNA
fold identically to that portion of the full-length molecule,
Figure 4(b). On the other hand, annealing had no effect on
the sensitivity of the 3′ 60 bases of BC1 RNA towards RNase
VI, Figure 5. Thus, these data demonstrate that the difference
in the conformer populations of annealed and unannealed
BC1 RNA most likely arise from alterations in the 5′ end of
the molecule.
We next examined whether FMRP preferentially bound
either of the dissected RNAs. Therefore, 35S-FMRP was
incubated with 2 μM annealed versions of each RNA; binding
was subsequently assessed by affinity capture and compared
to that of annealed full-length BC1 RNA. We found that the
5′ 75 bases of BC1 RNA bound slightly less, than full-length
BC1 RNA, Figure 6(a); however, the difference did not rise
to the level of statistical significance (P = .15, ANOVA).
Truncation of this RNA by a 15 base deletion at its 3′ end
further decreased binding (P = .08, ANOVA). Significantly,
this 60 base RNA is not expected to recapitulate the folding of
the first 60 bases of full-length BC1 RNA, Figure 6(b). On the
other hand, the 3′ 60 bases of BC1 RNA evinced no evidence
of binding, Figure 6(a). These data suggest that the major
determinant that FMRP recognizes in annealed BC1 RNA is
the hairpin structure of the 5′ end. To test this further, we also
conducted binding studies using an 85 base RNA harboring
the HIV1 TAR hairpin, Figure 6(c). The results show that this
RNA binds with the same affinity as annealed full-length BC1
RNA.
3.5. Specificity and Requirements of the FMRP BC1 RNA
Interaction. Different preparations or sources of FMRP has
been posited as a potential explanation for the divergent BC1
RNA-binding data obtained by different laboratories [59, 60]
and a likely cause of such differences is in the posttranslation
modifications that occur in each. To begin to address this
question, we examined whether differences in posttransla-
tional arginine methylation could alter the binding affinity of
annealed BC1 RNA and FMRP. Specifically, we compared the
Journal of Nucleic Acids 7
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Figure 4: Functional dissection of structural elements in the 5′ end of BC1 RNA. (a) Ten-fold serial treatment of annealed and unannealed
5′BC1-75 RNA with RNase VI starting at 0.1 units/μL (upper panel) or 0.5 units/μL (lower panel). Arrow marks the major conformer. Lane
M shows 100 bp molecular weight markers. (b) Secondary structure model of 5′BC1-75 RNA from M-fold.
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Figure 5: Functional dissection of structural elements in the 3′ end of BC1 RNA. (a) Ten-fold serial treatment of annealed and unannealed
3′BC1-60 RNA with RNase VI starting at 0.1 units/μL (upper panel) or 0.5 units/μL (lower panel). Arrow marks the major conformer. Lane
M shows 100 bp molecular weight markers. (b) Secondary structure model of 3′BC1-60 RNA from M-fold.

































































































Figure 6: Interaction of FMRP with the 5′ and 3′ ends of BC1 RNA. (a) 35S-FMRP was incubated with 2 μM annealed full-length BC1 RNA,
or annealed versions of the first 75 b of BC1 RNA (5′BC1-75), the first 60 b of BC1 RNA (5’BC1-60) the last 60 b of BC1 RNA (3′BC1-60)
and an 85 b transcript containing the HIV1 TAR hairpin. The percent binding corrected for background of 6 reactions per protein is plotted.
(b) Secondary structure model of 5′BC1-60 RNA from M-fold. (c) Secondary structure model of the HIV1 TAR RNA from M-fold; the 27 b
leader sequence has no effect upon the folding.
ability of full-length FMRP and the ability of an alternatively
spliced variant FMRPEx15c to bind 2 μM annealed BC1 RNA.
Previous studies showed that full-length FMRP is readily
methylated in its RG-rich region, while FMRP15c, which lacks
25 amino acids upstream of the RG-rich region, is refractory
to arginine methylation [66]. Figure 7(a) shows that binding
of annealed BC1 RNA to FMRP15c was less than it was to
full-length FMRP, but the difference did not rise to statistical
significance.
We next examined whether the binding between
annealed BC1 RNA and FMRP was unique. As an initial
indicator, 2 μM annealed BC1 RNA was incubated with
equimolar amounts of fragile X family members, 35S-FMRP,
35S-FXR1P and 35S-FXR2P (full-length forms); subsequently,
binding was assessed as previously described. As shown
in Figure 7(a), both FXR1P and FXR2P bound as well as
FMRP. To confirm and extend these results binding studies
between annealed BC1 RNA and luciferase or eIF4A were
performed. Luciferase does not contain any RNA-binding
motifs and does not bind to poly (rA), poly (rG), or eEF-
1A mRNA, Figure 7(b). Correspondingly, we found that
luciferase did not interact with annealed BC1 RNA. On the
other hand, the RNA helicase, eIF4A, bound weakly annealed
BC1 RNA under these conditions, Figure 7(a). These data
indicate that in addition to FMRP annealed BC1 RNA
can interact interchangeably with at least three other RNA-
binding proteins.
It has been previously proposed that BC1 RNA interacts
with the N-terminal domain (NTD) of FMRP [40]. Never-
theless, Wang et al. did not observe an interaction between
unannealed BC1 RNA and a 280 amino acid NTD construct,
FMRP1−280 [41]. To complete this analysis, we also assessed
the interaction of annealed BC1 RNA with FMRP1−280. As
shown in Figure 7(a), annealed BC1 RNA did not bind to
35S-FMRP1−280. To determine whether 35S-FMRP1−280 lacked
the ability to interact with RNA, we asked whether it could
to bind to homoribopolymers. As shown in Figure 7(c), 35S-
FMRP1−280 was unable to bind to poly(rA), poly(rG), or
poly(rI : rC). These data suggest that 35S-FMRP1−280 does
not significantly interact with ribonucleic acids under the
conditions used. Interestingly, however, while a shorter NTD,
that is, 35S-FMRP1−204, was also unable to bind to annealed
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Figure 7: Annealed BC1 RNA binds pleiotropically to the FXRPs. (a) Equimolar amounts of 35S-FMRP, 35S-FMRP15c,35S-FXR1P, 35S-FXR2P,
35S-eIF4A, 35S-FMRP280, 35S-FMRP204, and 35S-Luciferase were incubated with 2 μM annealed BC1 RNA. The percent binding corrected for
background of 6 reactions per protein is plotted. The relative levels of FMRP and FMRP15c, FMRP and FXR1P and FMRP and FXR2P were
not significantly different (P = .17, P = .67 and P = .27, resp., ANOVA). However, the relative levels of FMRP and eIF4A and FMRP and
NTD204 were significantly different (P = .038 and P = .007, resp., ANOVA). Since no binding above background was observed for NTD280
and Luciferase relative differences were not assessed. (b) Pull-down assays between 35S-luciferase and poly (rG), poly (rA), eEF1A RNA
(90 nM) and annealed BC1 RNA (5 μM) showing the unbound (U) and bound (B) fractions. Binding in the absence of RNA is shown for the
negative control. (c) Pull-down assays between 35S-NTD280 or 35S-NTD204 and poly (rG), poly (rA), poly (rI : rC) and annealed BC1 RNA
(5 μM) showing the unbound (U) and bound (B) fractions. Binding in the absence of RNA is shown for the negative control.
BC1 RNA, Figure 7(a), it was able to bind specifically to
poly(rG) and to a lesser extent, poly(rI : rC), Figure 7(c).
Thus, annealed BC1 RNA does not interact significantly with
the 204 N-terminal residues of FMRP.
4. Conclusions
Disparate data obtained using electrophoretic mobility shift
assays have been published concerning the binding of FMRP
to BC1 RNA [36, 40, 47]. To investigate this discrepancy,
we turned to an affinity capture assay to measure RNA
binding to FMRP under the assumption that the results
from different assays should converge to produce a common
result. This particular assay was first described by Boehlens
et al. and applied to the interactions of FMRP and nucleic
acids by Ashley et al. [51, 67]. Here, we demonstrate that
in 150 mM KCl and 125 mM NaCl, the assay has a dynamic
range of RNA binding of at least two logs. Thus, it is able to
distinguish high affinity binding from low affinity binding.
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We specifically developed these assay conditions, which
do not utilize tRNA as a general nonspecific binding
competitor, because it had previously been demonstrated
that both tRNA and BC1 RNA bind to FMRP in a low salt
buffer with nearly identical dissociation constants (Kds) [42],
and because tRNA was shown to directly displace BC1 RNA
from FMRP [47]. Thus, tRNA, while admittedly effective,
may not be the best blocking reagent for examining FMRP’s
interaction with BC1 RNA. On the other hand, FMRP’s
association with polyribosomes [37, 38], translationally
repressed ribosomes within neuronal granules [68], and its
function in translational regulation [17, 19, 27] indicates
that it operates in an environment with a relatively high
local concentration of tRNA, which would ensure a direct
competition with BC1 RNA. Indeed, previously published
immunoprecipitation experiments, which are carried out
in the presence of a large excess of tRNA (both added
and from the endogenous tRNA present during cell lysis)
and which fail to find BC1 RNA among the precipitated
transcripts are entirely consistent with a direct competition
between BC1 RNA and tRNA [47]. Here, we demonstrate
that BC1 RNA produced simply by in vitro transcription
does not interact with FMRP even in the absence of tRNA,
confirming our previous results using different assays and
different binding conditions [41]. Nevertheless, by artificially
annealing the BC1 RNA transcript, we found that binding
occurred although it was at least a hundred-fold weaker than
that between FMRP and eEF-1A mRNA. Previous protocols
examining the interaction between BC1 RNA and FMRP
have not indicated that the RNA was pretreated or annealed
before binding to FMRP was initiated [36, 40, 47]; therefore,
it must be assumed that it was not, and hence, this treatment
is unique to this work.
To try to understand the result, we first determined
whether enhanced binding due to annealing was a general
feature of FMRP’s interaction with RNA. A search of the
current literature produced mixed results. Darnell et al.,
working with kissing complex RNA a small double hairpin
with additional loop-loop tertiary interactions that binds to
FMRP’s KH2 domain, preannealed the RNA before binding
was initiated [30]. Likewise, Ramos et al. and Zanotti et
al. preannealed the synthetic G-rich RNA, sc1, to form
G-quartets before binding to RGG box peptides [69, 70].
Finally, Bechara et al. renatured SoSLIP RNA, a small
multiple hairpin-containing RNA, before they used it in
binding reactions with FMRP [19]. In contrast, longer RNAs
containing U-rich motifs such as MBP mRNA [71], the
FMR1 3′UTR [21], eEF-1A mRNA [17], and BMP receptor
mRNA [41] do not require preannealing to bind tightly
to FMRP. However, none of these studies directly compare
binding between annealed and unannealed RNAs. Therefore,
we examined the effect annealing eEF-1A mRNA had on
its binding to FMRP. Under conditions where FMRP’s
interaction with unannealed eEF-1A was linearly related
to the input RNA we found that preannealing the RNA
had no measurable effect upon the binding. Thus, while
not a general requirement for FMRP binding preannealing
may be necessary for smaller RNAs whose structure is
more susceptible to changes in temperature, buffer pH,
concentration and type of ions and RNA concentration [70].
We next determined whether annealed BC1 RNA was
structurally altered from unannealed BC1 RNA. Indeed,
we showed that the annealed form exhibited an increased
susceptibility to cleavage by RNase VI. These data support the
hypothesis that a particular BC1 RNA conformer; that is, one
containing a unique doubled-stranded RNA structure was
the true FMRP interactor. Functional dissection of BC1 RNA
into either a 5′ ID element or a 3′ element demonstrated that
the major determinant that FMRP binds to is located in the
5′ 75 bases of the molecule. As FMRP also binds to tRNA and
TAR RNA, these data imply that FMRP can weakly recognize
hairpin-containing RNAs.
Another difference between the published FMRP BC1
RNA interaction studies was that one group used full-
length recombinant FMRP produced from baculovirus [36,
40], while the other group used full-length recombinant
FMRP produced in E. coli [47]. A potential concern here
is that each of these preparations may be differentially
posttranslationally modified. Indeed, it is well known that
FMRP is subject to posttranslational methylation of arginine
residues in its RG-rich region [18, 31]. However, while
protein arginine methyltransferases are present in Spodoptera
frugiperda [72], the host cells used in baculovirus FMRP
production [40], they are absent from E. coli [73, 74]. Thus,
it is possible that the presence or absence of methyl-arginine
residues might directly or indirectly affect an interaction
between FMRP and BC1 RNA. In the present work, we
opted to produce full-length FMRP in rabbit reticulocyte
lysates (RRL), which generates partially methylated FMRP
[66]. Again, we assumed that posttranslational modifications
arising from source differences could be a modulating but
not the determining factor in a putative FMRP BC1 RNA
interaction. Precedence for this assumption may be seen in
the work of Stetler et al. who showed that methylating FMRP
decreased, but did not abrogate, the direct binding of two
G-quartet RNAs to FMRP’s RG-rich region [56]. Consistent
with the work using E. coli-purified FMRP [47] and with the
work of Wang et al. who used unmethylated FMRP produced
in cell-free wheat germ lysates to examine BC1 RNA
binding [41], we observed minimal interactions between
RRL-produced FMRP and unannealed BC1 RNA. Thus,
methylating FMRP’s arginine residues does not enhance its
affinity for unannealed BC1 RNA. Furthermore, although
binding between annealed BC1 RNA and the methylation
refractory form of FMRP (FMRP15c) was reduced compared
to methylated FMRP, it was not a statistically significant
reduction. Thus, methylarginine residues in FMRP’s RG-rich
region are not absolutely required for this interaction either.
We also probed the exclusivity of FMRP’s interaction
with annealed BC1 RNA. Here, we found that interactions
of similar magnitude occur with fragile X paralogs FXR1P
and FXR2P and to a lesser extent, eIF4A. These results
demonstrate that BC1 RNA binds indiscriminately to RNA-
binding proteins. Interestingly, contrasting results were
recently obtained for kissing complex (kc) RNA [34], where
it was shown that this RNA exclusively interacts with the
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fragile X paralogs but not with other related KH domain-
containing RNA-binding proteins.
As all three paralogs have highly homologous N-terminal
sequences but are more divergent in their C-terminal ends
[75], we inquired whether annealed BC1 RNA interacted
with specific N-terminal fragments of FMRP (NTDs). We
did not observe an interaction between annealed BC1 RNA
and FMRP1−280, a construct comprising both N-terminal
residues and the first KH domain (KH1). The results were
consistent with previous work showing that this construct
did not interact with unannealed BC1 RNA [41]. However,
as FMRP1−280 did not interact with other nucleic acids
under these conditions, we could not rule out the possibility
that the protein was mis-folded although previous physical
evidence suggests this is not the case [50]. Therefore, we
also examined the interaction between annealed BC1 RNA
and FMRP1−204, a construct that does interact with nucleic
acids and is expected “to be at least partially folded and
be monodisperse” under the conditions it was used [50].
Nevertheless, annealed BC1 RNA did not interact with this
FMRP fragment either. Hence, the first 204 residues of
FMRP, which includes two Tudor domains and an alpha helix
that is essential for domain stability [76], are not required
for the interaction of annealed BC1 RNA with FMRP. Using
different conditions, Zalfa et al. have suggested that BC1
RNA binds to an NTD comprising amino acids 1–217 [40].
The additional 13 residues of this construct comprise part of
another alpha helix, which stabilizes the folding of FMRP’s
KH1 domain [50]. While it is possible that amino acids 205–
217 may confer binding specificity to annealed BC1 RNA,
Zalfa et al. showed that a construct comprising this alpha
helix along with the KH1 domain (residues 205–280) did
not interact with BC1 RNA [40]. However, additional studies
using other constructs will be needed to fully address the
question of which FMRP residues are necessary and sufficient
for its interaction with annealed BC1 RNA.
Although we demonstrate an in vitro interaction between
FMRP and BC1 RNA, its nature and its physiological
significance remain elusive. For example, the structure of the
unique BC1 RNA conformer that FMRP binds to has not
been defined other than the fact that it contains double-
stranded RNA and is primarily found in the 5′ half of the
molecule. In fact, it is possible based on the rather high
RNA concentrations used in the annealing reaction that
FMRP may be interacting with a dimer of BC1 RNA. This
would be analogous to the formation of intermolecular G-
quartet RNAs such as MAP1B RNA [69]. Clearly, a more
comprehensive biophysical analysis of the parameters of this
interaction is needed to fully address this issue. Regardless,
the ultimate significance of this observation is questionable
given that the formation of this conformer does not occur
at temperatures that mammalian cells can survive. Although
one might postulate that a chaperone protein may be able to
mitigate the temperature requirement for annealing [77, 78],
it is clear that FMRP cannot be this chaperone, because it is
unable convert unannealed BC1 RNA into a molecule that
it binds under physiological conditions. Given this, our data
generated using different constructs, different preparations
and different methods, converge with the published work of
Iacoangeli et al. [47] to support a model in which FMRP
and BC1 RNA operate independently of each other to control
protein synthesis in neuronal processes.
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